Description
Springer Helicobacter pylori 1990 Proceedings of the Second International Symposium on Helicobacter pylori Bad Nauheim August 2526th 1989 1st Editon 2011 Softbound by Heinz Menge, M. Gregor, Guido N.J. Tytgat, Barry J. Marshall, Cliodna A.M. McNulty
Section 1 Virulence Factors and Pathogenicity of Helicobacter pylori.- Urease and Catalase as Virulence Factors of Helicobacter pylori.- Discussion.- Adhesion Properties of Helicobacter pylori.- Helicobacter pylori Hemagglutinins.- Discussion.- Cytotoxic Activity of Helicobacter pylori.- Discussion.- Helicobacter pylori and Gastric Mucus Integrity.- Discussion.- Helicobacter pylori and Other Gastric Spirilla: Similarities and Differences.- Further Observations on Human Spirobacteria.- Discussion.- Animal Models of Helicobacter pylori Gastritis.- Discussion.- Isotype and Specificity of Local and Systemic Anti-Helicobacter pylori Antibodies.- Discussion.- Section 2 Epidemiology of Helicobacter pylori.- Survival of Helicobacter pylori in the Aquatic Environment.- Discussion.- Helicobacter pylori in Human Populations: The Present and Predictions of the Future Based on the Epidemiology of Polio.- Discussion.- Transmission and Sources of Helicobacter pylori.- Discussion.- Chronic Gastritis: Epidemiology and Relationship to Peptic Ulcer Diseases.- Gastritis Epidemiology and Natural History.- Discussion.- Epidemiology of Gastric Metaplasia.- Discussion.- Epidemiology of Duodenal Ulcer Disease.- Discussion.- Section 3 Theoretical Site of Helicobacter pylori Therapy.- In Vitro Sensitivity of Helicobacter pylori.- Discussion.- Antibiotic Concentrations in Gastric Mucosa: The Guinea Pig Model.- Discussion.- Acquired Resistance to Antibiotics: An Underestimated Cause of Failure in the Treatment of Helicobacter pylori Infection.- Discussion.- Clinical Pharmacology of Bismuth - Studies from the Royal Free Hospital.- The Absorption of Bismuth from Orally Administered Tripotassium Dicitrato Bismuthate and Bismuth Subsalicylate.- Pharmacokinetics of Bismuth Compounds in Patients with Gastritis and Ulcer Disease During Standard Treatment.- Discussion.- Pharmacology and Safety of Bismuth Compounds.- Discussion.- Section 4 Clinical Trials for Helicobacter pylori Treatment.- Treatment Regimens to Eradicate Helicobacter pylori.- Discussion.- Effect of Eradication of Helicobacter pylori on Nonulcer Dyspepsia Syndrome and Chronic Gastritis.- Discussion.- Section 5 Optimal Design of Clinical Trials.- Histological Definition and Scoring of Gastritis.- Discussion.- Measuring Symptoms in Helicobacter pylori-Associated Gastritis and Non-Ulcer Dyspepsia.- Discussion.- Optimal Study Design for Therapeutic Trials in Helicobacter pylori- Associated Nonulcer Dyspepsia.- Discussion.- Optimal Design for Peptic Ulcer Studies.- Discussion.